Identifying Risk Factors and Predicting Future Health Outcomes for Korean Patients With Heart and Blood Vessel Diseases: A Long-term Follow-up Study

April 23, 2026 updated by: Samsung Medical Center

PRIME (Precision Registry for Integrated Cardio-cerebrovascular Medicine & Evidence)

This study aims to establish a comprehensive, long-term clinical registry infrastructure for heart and brain vascular diseases (cardiovascular diseases and stroke) at Samsung Medical Center. In South Korea, these diseases are a leading cause of death, with a rapidly increasing burden due to an aging population and changing lifestyles. Despite this, there is a lack of large-scale, systematic data specifically focused on the long-term clinical course and unique characteristics of Korean patients.

The central hypothesis of this study is that the establishment of a standardized registry infrastructure-integrating both retrospective (historical) and prospective (future) data collection-will provide a more accurate and comprehensive understanding of the natural history and risk factors of heart and brain vascular diseases in the Korean population than currently available fragmented data. By combining existing medical records with ongoing patient follow-up, this infrastructure will serve as a critical scientific platform for developing personalized prevention and precision medicine strategies.

By building this organized data collection system, the study will:

Construct a robust infrastructure to collect uniform, high-quality clinical data, encompassing both past medical history (retrospective) and future clinical progress (prospective) from a large population of Korean patients.

Monitor long-term health outcomes and the progression of diseases by tracking patients over many years.

Analyze the interaction between various risk factors and patient outcomes to identify population-specific patterns.

Create a scalable platform that can integrate advanced technologies, such as multi-omics and digital health tools, for future research.

Ultimately, this integrated registry infrastructure is expected to provide the essential scientific evidence needed to optimize clinical guidelines and improve the long-term quality of life for patients with heart and brain vascular diseases in Korea.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

800000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

The study population consists of patients diagnosed with or treated for heart and brain vascular diseases (cardiovascular diseases and stroke) at Samsung Medical Center, a tertiary academic hospital in Seoul, Korea.

This cohort includes:

Retrospective Group: Patients with clinical records within the hospital's historical database to analyze past clinical courses and long-term outcomes.

Prospective Group: Patients newly visiting or currently under follow-up care at the heart, stroke, and vascular centers who consent to long-term monitoring.

The population covers a wide clinical spectrum, from acute emergency cases (e.g., myocardial infarction, ischemic stroke) to chronic management.

Description

Inclusion Criteria:

A patient who visited Samsung Medical Center due to cardiovascular and cerebrovascular disease.

Exclusion Criteria:

A patient deemed unable to participate in the study based on the judgment of the medical staff.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of Major Adverse Cardio-Cerebrovascular Events (MACCE)
Time Frame: Up to 20 years (from the date of enrollment until the end of the follow-up period)
Up to 20 years (from the date of enrollment until the end of the follow-up period)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Samsung Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 2, 2026

Primary Completion (Estimated)

November 27, 2026

Study Completion (Estimated)

December 31, 2040

Study Registration Dates

First Submitted

January 30, 2026

First Submitted That Met QC Criteria

January 30, 2026

First Posted (Actual)

February 6, 2026

Study Record Updates

Last Update Posted (Actual)

April 28, 2026

Last Update Submitted That Met QC Criteria

April 23, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SMC IRB 2025-12-061

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebro Vascular Disease

Clinical Trials on Standard Medical Therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe